guselkumab is a selectively blocking agent for interleukin-23 (IL-23), a cytokine involved in plaque psoriasis. guselkumab was approved by FDA as an anti-inflammatory drug for the treatment of moderate to severe plaque psoriasis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.